About
Gene Therapy and Immunotherapy Company. Lentiviral Vector Platform and Indication-Specific Technologies. Lead Therapeutics for an HIV Cure, Liver Cancer Cure, and PKU therapy
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapyStem Cell & Cellular TherapyVirginia, DC, DE & Maryland
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
45
By Phase
PHASE1: 1
By Status
UNKNOWN: 2ENROLLING_BY_INVITATION: 1COMPLETED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
Today
Hover over trial bars to see details
Recent Trials
NCT05529342Lead Sponsor
Long-term Follow-up of Study Participant Treated With Lentiviral-Based Genetically Modified Autologous Cell Product ,AGT103-T
N/AEnrolling by invitation
7 participants
Started: Aug 29, 2022 · Completed: Sep 29, 2038
NCT05540964Lead Sponsor
An Antiretroviral Treatment Interruption (ATI) Study to Evaluate the Impact of Genetically Modified Autologous Cells (AGT103-T) to Suppress Human Immunodeficiency Virus Replication in the Absence of Antiretroviral Therapy
N/AUnknown
7 participants
Started: Jul 19, 2022 · Completed: Jul 19, 2025
NCT04561258Lead Sponsor
Study to Evaluate the Safety of a Gene and Cell Therapy Product in Participants With HIV That is Well-Controlled on Antiretroviral Therapy
PHASE1Completed
7 participants
Started: Oct 12, 2020 · Completed: Nov 21, 2022
NCT03215004Lead Sponsor
Developing a Functional Cure for HIV Disease: Clinical Specimen Collection From HIV Positive Individuals
N/AUnknown
24 participants
Started: Jul 25, 2017 · Completed: Feb 7, 2021
Locations (1)
Headquarters
Rockville, MD, United States
Map
Loading map...